Infasurf

Infasurf

Manufacturer:

ONY

Distributor:

Pharm-D
Concise Prescribing Info
Contents
Calfactant (total phospholipids 35 mg/mL, proteins 0.7 mg including SP-B 0.26 mg)
Indications/Uses
Prevention of resp distress syndrome (RDS) in premature infants at high risk for RDS & treatment ("rescue") of premature infants who develop RDS. Decreases the incidence of RDS, mortality due to RDS & air leaks associated w/ RDS. Prophylaxis therapy at birth for premature infants <29 wk of gestational age at significant risk for RDS. Treatment therapy for infants ≤72 hr of age w/ RDS (confirmed by clinical & radiologic findings) & requiring endotracheal intubation.
Dosage/Direction for Use
3 mL/kg at birth every 12 hr for total of up to 3 doses.
Special Precautions
Not a substitute for neonatal intensive care. Monitor resp status regularly. Transient episodes of reflux into the endotracheal tube, cyanosis, bradycardia or airway obstruction. Patients w/ both intraventricular hemorrhage (IVH) & periventricular leukomalacia (PVL).
Adverse Reactions
Cyanosis, airway obstruction, bradycardia, reflux of surfactant into the endotracheal tube, requirement for manual ventilation & reintubation.
MIMS Class
Other Drugs Acting on the Respiratory System
ATC Classification
R07AA - Lung surfactants ; Used in the treatment of respiratory diseases.
Presentation/Packing
Form
Infasurf intratracheal susp
Packing/Price
6 mL x 1's
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Already a member? Sign in
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Already a member? Sign in